Researchers have identified genetic signatures that may explain the ethnic differences in the severity of prostate cancer, particularly in sub-Saharan Africa. In two studies published in Nature and Genome Medicine, researchers detailed how they used genetic sequencing of prostate cancer tumors from Australian, Brazilian, and South African donors to identify a new prostate cancer taxonomy and cancer drivers that not only distinguish patients by genetic ancestry, but also predict which cancers are likely ...
Phenotypic Precision Medicine in Advanced Prostate Cancer
Advertisement
Latest News
Men with a benign histology after TURP have a low risk of aggressive prostate cancer and do not require extensive monitoring.
Combining metformin with testosterone replacement therapy was shown to reduce the effects of prostate and colorectal cancers.
Data from the STOMP and ORIOLE trials showed that many OMPC patients will experience durable response to therapy.
Researchers sought to assess the link associations between coffee intake, caffeine metabolism genotype, and survival.
Nitric oxide exposure may play a key role in the development of prostate cancer.
Few biomarkers predict therapeutic response to radiation or adjunctive treatments in PCa patients treated with radiotherapy.
Advertisement
Roundtable Discussions
Prostate Cancer Knowledge Hubs
Curated clinical content on prostate cancer types, therapies, and technologies
Conference Coverage
Neoadjuvant platinum-based chemotherapy has been found effective for treating metastatic penile squamous cell carcinoma.
A new study has found an association between neurodevelopmental disorders and testicular seminoma.
CLEAR study results showed that treatment with first-line lenvatinib plus pembrolizumab had clinical benefit at 2 years.
The RACE IT trial finds neoadjuvant radio-immunotherapy followed by radical cystectomy a safe and feasible treatment option.
Patients with mCRPC with AR alterations had significantly worse survival outcomes compared with patients with wild-type.
A meta-analysis found that triplet regimens with darolutamide and APP improved survival in mCSPC with high volume of disease.
Advertisement
Advertisement
Trending
The first PET scans using Illuccix, Telix’s PSMA-PET imaging agent, have been carried out in cooperation with BAMF Health.
Nanobubbles can target membrane proteins, including PSMA, to bind to receptors that are overexpressed in cancer cells.
A Th1 multiantigen vaccine was more effective at inhibiting PSMA prostate cancer growth than single antigen vaccines.
